Dr. Olga Nissan Joins Evogene as Vice President
Evogene Ltd. (Nasdaq: EVGN), a groundbreaking company specializing in computational chemistry for pharmaceuticals and agricultural industries, proudly announces the appointment of Dr. Olga Nissan as its new Vice President of Business Development. Her role will officially begin on January 1, 2026.
A Seasoned Biotechnology Expert
Dr. Nissan brings a wealth of experience to her new position. She is an accomplished executive with a background in biotechnology and pharmaceuticals, focusing on bridging the gap between scientific research and business applications. Her extensive experience encompasses R&D, clinical development, and business operations within pharmaceutical, diagnostics, and agri-biotechnology sectors.
Previous Roles and Achievements
In her impressive career, Dr. Nissan has served in various leadership roles. She co-founded Protica Bio, where she acted as CEO, driving innovation and business strategies. Additionally, she has held positions such as Technology Manager at EcoPhage, Senior Scientist at BiomX, and QC Domain Manager at Teva Pharmaceutical Industries. This diverse background equips her with invaluable insights into both drug development and corporate dynamics.
Education and Expertise
Dr. Nissan holds a PhD and has completed postdoctoral research in biochemistry and proteomics from the noted Weizmann Institute of Science. This solid educational foundation complements her industry experience, allowing her to align scientific developments with practical market needs.
A Vision for the Future
Expressing her enthusiasm about joining Evogene, Dr. Nissan stated, "I am excited to join Evogene at a pivotal time in its expansion. The company's commitment to translating cutting-edge, AI-driven science into meaningful small-molecule-based therapeutic value aligns perfectly with my experience across pharma and biotech. I look forward to collaborating on strategic partnerships, accelerating innovative discovery programs, and working alongside Evogene's talented team to enhance patient solutions globally."
Company Leadership's Confidence
Mr. Ofer Haviv, Evogene's President and CEO, expressed his excitement regarding Dr. Nissan’s addition to the leadership team, saying, "We are delighted to welcome Dr. Olga Nissan to Evogene's leadership team. With over 15 years of experience in biotech, pharma, and AI-enabled drug discovery, her unique combination of scientific depth and business development leadership is a tremendous asset. We believe her capabilities will greatly enhance our small-molecule discovery and optimization, powered by our ChemPass AI tech-engine, and help expand our collaborations with industry leaders to translate real-world innovation into significant value."
About Evogene Ltd.
Evogene Ltd. (Nasdaq: EVGN) continues to lead the way in computational chemistry. Its focus is on the generative design of highly potent small molecules that cater to the pharmaceutical and agricultural industries.
Central to Evogene’s innovative technology is ChemPass AI, a proprietary generative AI engine designed to create novel small molecules. This engine significantly improves development success rates while optimizing time and resources.
By combining advanced technology with strategic partnerships and in-house development, Evogene is committed to delivering breakthrough products that satisfy real-world industry needs, embodying their concept of "Real-World Innovation."
Contact Information
For investors seeking further information, please contact Evogene's investor relations. The company is available via telephone at +972-8-9311901.
Frequently Asked Questions
Who is Dr. Olga Nissan?
Dr. Olga Nissan is a seasoned biotechnology executive with extensive experience in R&D and business operations in pharmaceutical and agri-biotechnology sectors.
What role will Dr. Nissan have at Evogene?
Dr. Nissan will serve as the Vice President of Business Development, focusing on building partnerships and advancing Evogene’s innovative programs.
What is Evogene's primary area of expertise?
Evogene specializes in computational chemistry and the generative design of small molecules for pharmaceuticals and agriculture.
What technology underpins Evogene’s operations?
Evogene utilizes ChemPass AI, a proprietary generative AI engine to design potent small molecules efficiently.
How can I contact Evogene for investor inquiries?
Investors can contact Evogene's investor relations at +972-8-9311901 for further information or inquiries.
